The original version of this article unfortunately contained a mistake. The second sentence of the section “irAEs and ICI efficacy” should read as.
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5) / Naqash A.R.; Ricciuti B.; Owen D.H.; Florou V.; Toi Y.; Cherry C.; Hafiz M.; De Giglio A.; Muzaffar M.; Patel S.H.; Sugawara S.; Burkart J.; Park W.; Chiari R.; Sugisaka J.; Otterson G.A.; de Lima Lopes G.; Walker P.R.. - In: CANCER IMMUNOLOGY, IMMUNOTHERAPY. - ISSN 0340-7004. - ELETTRONICO. - 69:7(2020), pp. 1189-1189. [10.1007/s00262-020-02582-z]
Correction to: Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort (Cancer Immunology, Immunotherapy, (2020), 69, 7, (1177-1187), 10.1007/s00262-020-02536-5)
Ricciuti B.;De Giglio A.;
2020
Abstract
The original version of this article unfortunately contained a mistake. The second sentence of the section “irAEs and ICI efficacy” should read as.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
